This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Catching you up on the stories you need to know this morning, mass shooting victims testify on Capitol Hill, the White House outlines its plan to vaccinate kids younger than five years old, and we break down how to protect yourself from monkeypox.
The pharmaceutical giant Moderna says its updated 'bivalent' booster shot provides a stronger immune response against the Omicron variant of COVID-19 specifically. This week, Moderna plans to submit preliminary data to U.S. health officials in the hopes that its new booster will be available later this summer. Dr. Sampson Davis, emergency medicine physician, joins Cheddar News to discuss.
NASA has announced that the first official full-color images will be beamed back to Earth from the James Webb Telescope on July 12. Gregory L. Robinson, the director of the James Webb Space Telescope Program in the NASA Science Mission Directorate, joined Cheddar News to discuss the anticipated image drop. “We expect to see the universe different," he said. "Webb will allow us to see much, much clearer and deeper into the universe."
On this episode of Cheddar Reveals, Professor Laurence Hurst, Director of The Milner Centre for Evolution, discusses the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up? Neville Sanjana, faculty member at NY Genome and New York University, breaks down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases; Cheddar gets a look at Curiosity Stream's 'The Butterfly Effect.'
Neville Sanjana, faculty member at NY Genome and New York University, joins Cheddar Reveals to break down the latest innovations in CRISPR genetic engineering and its applications from 'designer babies' to curing genetic conditions and diseases.
Professor Laurence Hurst, Director of The Milner Centre for Evolution, joins Cheddar Reveals to discuss the mystery of human evolution that's still baffling scientists: why are humans still evolving, and why has the process sped up?
It can be tough to make sustainable choices, and even harder when sustainable materials don't hold up. Loliware has a solution to the plastic straw problem: its seaweed-based straws are stronger than paper alternatives and once used, can be composted and return to the earth or sea without causing harm. Sea Briganti, CEO of Loliware, joins Closing Bell to discuss the tech behind the straws, new product launches, and more.
Umbilical cord blood banking platform Anja Health raised $4.5 million dollars in a seed round led by Seven Seven Six, a venture capital firm founded by Reddit co-founder Alexis Ohanian. Anja Health offers a personalized, doctor-backed cord blood bank, which lets new parents freeze stem cells from their child's umbilical cord so they can be used to treat diseases in the future. It's a process Anja has called 'Hollywood's best-kept secret,' as celebrities like Kylie Jenner, Serena Williams, and more have all banked their umbilical cord blood. Kathryn Cross, the founder of Anja Health, joins Cheddar News' Closing Bell to discuss.
After learning that the suspect in the Uvalde school shooting posted about his intentions on Facebook, activists are urging social networks to make changes. Lena Derhally, a licensed psychotherapist and author of "The Facebook Narcissist," joined Cheddar News to discuss the role social media plays in school shootings. "They're not really invested in taking down hateful content," she said about social platforms."In regards to the shooting, it was 15 minutes before that actual threat. It would be pretty hard for a social media company to trace that threat that quickly. But what they can do better is take down threats and hateful content much faster and more than they're doing now."
Esper Bionics CEO Dima Gazda breaks down how they're creating a mind-controlled bionic hand that guest smarter the more you use it, and what this innovation means for the future of the prosthetics industry.
